Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.39 |
| ▸ | CCR8 | P51685 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13943232 | 0.75 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTPARP1EGLN1 | |
| SCHEMBL644794 | 0.75 | ALDH1A1 (0.68) | ALDH1A1KDM4EMAPTPARP1EGLN1 | |
| SCHEMBL644758 | 0.74 | ALDH1A1 (0.45) | ALDH1A1KDM4EEGLN1HTTSMN1; SMN2 | |
| SCHEMBL12082627 | 0.72 | CDC25B (0.47) | MAPTHTTTDP1L3MBTL1NPC1 | |
| SCHEMBL15445449 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTPARP1EGLN1 | |
| SCHEMBL3502575 | 0.72 | KDM4E (0.56) | ALDH1A1KDM4EEGLN1LMNAHTT | |
| SCHEMBL11053021 | 0.71 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTLMNAHTT | |
| SCHEMBL14136247 | 0.71 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTPARP1EGLN1 | |
| SCHEMBL9983599 | 0.71 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTPARP1EGLN1 | |
| SCHEMBL10014903 | 0.70 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTPARP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | ALDH1A1 899/4885KDM4E 3836/4885MAPT 2162/4885 |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ADRA2C, ADRA2B, ADRB3 | ALDH1A1 1423/4885KDM4E 3646/4885MAPT 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.